1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2017 VS 2021 VS 2030
1.2.2 Next Generation Sequencing
1.2.3 qPCR & Multiplexing
1.2.4 DNA Microarrays
1.2.5 Others
1.3 Market by Application
1.3.1 Global Next Generation Cancer Diagnostics Market Share by Application: 2017 VS 2021 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Next Generation Cancer Diagnostics Market Perspective (2017-2030)
2.2 Next Generation Cancer Diagnostics Growth Trends by Region
2.2.1 Next Generation Cancer Diagnostics Market Size by Region: 2017 VS 2021 VS 2030
2.2.2 Next Generation Cancer Diagnostics Historic Market Size by Region (2017-2023)
2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Region (2023-2030)
2.3 Next Generation Cancer Diagnostics Market Dynamics
2.3.1 Next Generation Cancer Diagnostics Industry Trends
2.3.2 Next Generation Cancer Diagnostics Market Drivers
2.3.3 Next Generation Cancer Diagnostics Market Challenges
2.3.4 Next Generation Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next Generation Cancer Diagnostics Players by Revenue
3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2017-2023)
3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2017-2023)
3.2 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
3.4 Global Next Generation Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2021
3.5 Next Generation Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Next Generation Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Next Generation Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next Generation Cancer Diagnostics Breakdown Data by Type
4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2017-2023)
4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2023-2030)
5 Next Generation Cancer Diagnostics Breakdown Data by Application
5.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2017-2023)
5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Next Generation Cancer Diagnostics Market Size (2017-2030)
6.2 North America Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
6.3 North America Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Next Generation Cancer Diagnostics Market Size (2017-2030)
7.2 Europe Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
7.3 Europe Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2017-2030)
8.2 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
8.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Next Generation Cancer Diagnostics Market Size (2017-2030)
9.2 Latin America Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
9.3 Latin America Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2017-2030)
10.2 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2017-2023)
10.3 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Cepheid
11.1.1 Cepheid Company Detail
11.1.2 Cepheid Business Overview
11.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
11.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.1.5 Cepheid Recent Development
11.2 Koninklijke Philips N.V
11.2.1 Koninklijke Philips N.V Company Detail
11.2.2 Koninklijke Philips N.V Business Overview
11.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
11.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.2.5 Koninklijke Philips N.V Recent Development
11.3 F. Hoffmann-La Roche Ltd
11.3.1 F. Hoffmann-La Roche Ltd Company Detail
11.3.2 F. Hoffmann-La Roche Ltd Business Overview
11.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
11.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.3.5 F. Hoffmann-La Roche Ltd Recent Development
11.4 Qiagen
11.4.1 Qiagen Company Detail
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
11.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.4.5 Qiagen Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
11.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.5.5 Novartis AG Recent Development
11.6 Abbott
11.6.1 Abbott Company Detail
11.6.2 Abbott Business Overview
11.6.3 Abbott Next Generation Cancer Diagnostics Introduction
11.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.6.5 Abbott Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
11.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Opko Health
11.8.1 Opko Health Company Detail
11.8.2 Opko Health Business Overview
11.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
11.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.8.5 Opko Health Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Detail
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
11.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.9.5 Myriad Genetics Recent Development
11.10 Agilent Technologies
11.10.1 Agilent Technologies Company Detail
11.10.2 Agilent Technologies Business Overview
11.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
11.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.10.5 Agilent Technologies Recent Development
11.11 GE Healthcare
11.11.1 GE Healthcare Company Detail
11.11.2 GE Healthcare Business Overview
11.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
11.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.11.5 GE Healthcare Recent Development
11.12 PerkinElmer
11.12.1 PerkinElmer Company Detail
11.12.2 PerkinElmer Business Overview
11.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
11.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.12.5 PerkinElmer Recent Development
11.13 Genomic Health
11.13.1 Genomic Health Company Detail
11.13.2 Genomic Health Business Overview
11.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
11.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.13.5 Genomic Health Recent Development
11.14 Illumina
11.14.1 Illumina Company Detail
11.14.2 Illumina Business Overview
11.14.3 Illumina Next Generation Cancer Diagnostics Introduction
11.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.14.5 Illumina Recent Development
11.15 Hologic
11.15.1 Hologic Company Detail
11.15.2 Hologic Business Overview
11.15.3 Hologic Next Generation Cancer Diagnostics Introduction
11.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.15.5 Hologic Recent Development
11.16 Almac Group
11.16.1 Almac Group Company Detail
11.16.2 Almac Group Business Overview
11.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
11.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.16.5 Almac Group Recent Development
11.17 Janssen Global Services
11.17.1 Janssen Global Services Company Detail
11.17.2 Janssen Global Services Business Overview
11.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
11.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.17.5 Janssen Global Services Recent Development
11.18 Sysmex Corporation
11.18.1 Sysmex Corporation Company Detail
11.18.2 Sysmex Corporation Business Overview
11.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
11.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2017-2023)
11.18.5 Sysmex Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
